These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 35881197)
41. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy. Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127 [TBL] [Abstract][Full Text] [Related]
42. Molecular determinants of response to PD-L1 blockade across tumor types. Banchereau R; Leng N; Zill O; Sokol E; Liu G; Pavlick D; Maund S; Liu LF; Kadel E; Baldwin N; Jhunjhunwala S; Nickles D; Assaf ZJ; Bower D; Patil N; McCleland M; Shames D; Molinero L; Huseni M; Sanjabi S; Cummings C; Mellman I; Mariathasan S; Hegde P; Powles T Nat Commun; 2021 Jun; 12(1):3969. PubMed ID: 34172722 [TBL] [Abstract][Full Text] [Related]
44. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression]. Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965 [TBL] [Abstract][Full Text] [Related]
45. Tumor immune microenvironment in odontogenic carcinomas: Evaluation of the therapeutic potential of immune checkpoint blockade. Oh KY; Hong SD; Yoon HJ J Oral Pathol Med; 2024 Mar; 53(3):217-225. PubMed ID: 38449350 [TBL] [Abstract][Full Text] [Related]
46. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603 [TBL] [Abstract][Full Text] [Related]
47. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248 [TBL] [Abstract][Full Text] [Related]
48. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039 [TBL] [Abstract][Full Text] [Related]
49. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. Hwang M; Canzoniero JV; Rosner S; Zhang G; White JR; Belcaid Z; Cherry C; Balan A; Pereira G; Curry A; Niknafs N; Zhang J; Smith KN; Sivapalan L; Chaft JE; Reuss JE; Marrone K; Murray JC; Li QK; Lam V; Levy BP; Hann C; Velculescu VE; Brahmer JR; Forde PM; Seiwert T; Anagnostou V J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688557 [TBL] [Abstract][Full Text] [Related]
50. [Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer]. Zheng Y; Jiang W; Li J; Dai L; Chen D; Li Y; Huang L; Wang M Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):671-677. PubMed ID: 36172732 [TBL] [Abstract][Full Text] [Related]
51. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363 [TBL] [Abstract][Full Text] [Related]
52. Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression. Kobayashi K; Seike M; Zou F; Noro R; Chiba M; Ishikawa A; Kunugi S; Kubota K; Gemma A Anticancer Res; 2018 Feb; 38(2):753-762. PubMed ID: 29374699 [TBL] [Abstract][Full Text] [Related]
53. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J Front Immunol; 2020; 11():1173. PubMed ID: 32587591 [No Abstract] [Full Text] [Related]
54. Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology? Meshulami N; Tavolacci S; de Miguel-Perez D; Rolfo C; Mack PC; Hirsch FR Clin Lung Cancer; 2023 Jul; 24(5):401-406. PubMed ID: 37208221 [TBL] [Abstract][Full Text] [Related]
55. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261 [TBL] [Abstract][Full Text] [Related]
56. Dynamic changes in PD-L1 expression and CD8 Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259 [TBL] [Abstract][Full Text] [Related]
57. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer. van de Haar J; Mankor JM; Hummelink K; Monkhorst K; Smit EF; Wessels LFA; Cuppen E; Aerts JGJV; Voest EE Clin Cancer Res; 2024 Apr; 30(7):1307-1318. PubMed ID: 38300729 [TBL] [Abstract][Full Text] [Related]
58. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694 [TBL] [Abstract][Full Text] [Related]
59. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens. Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792 [TBL] [Abstract][Full Text] [Related]
60. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer. Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]